Skip to main content
Journal cover image

Alterations in brain TREM2 and Amyloid-β levels are associated with neurocognitive impairment in HIV-infected persons on antiretroviral therapy.

Publication ,  Journal Article
Fields, JA; Spencer, B; Swinton, M; Qvale, EM; Marquine, MJ; Alexeeva, A; Gough, S; Soontornniyomkij, B; Valera, E; Masliah, E; Achim, CL; Desplats, P
Published in: J Neurochem
December 2018

Neuroinflammation is a common pathological correlate of HIV-associated neurocognitive disorders (HAND) in individuals on antiretroviral therapy (ART). Triggering receptor expressed on myeloid cells 2 (TREM2) regulates neuroinflammation, clears extracellular Amyloid (A)-β, surveys for damaged neurons, and orchestrates microglial differentiation. TREM2 has not been studied in HIV+ brain tissues. In this retrospective study, we investigated TREM2 expression levels and localization to microglia, Aβ protein levels, and tumor necrosis factor (TNF)-α transcript levels in the frontal cortices of 52 HIV+ decedents. All donors had been on ART; 14 were cognitively normal (CN), 17 had an asymptomatic neurocognitive impairment (ANI), and 21 had a minor neurocognitive disorder (MND). Total TREM2 protein levels were increased in the soluble and decreased in the membrane-enriched fractions of MND brain tissues compared to CN; however, brains from MND Hispanics showed the most robust alterations in TREM2 as well as significantly increased TNF-α mRNA and Aβ levels when compared to CN Hispanics. Significant alterations in the expression of total TREM2 protein and transcripts for TNF-α were not observed in non-Hispanics, despite higher levels of Aβ in the non-Hispanic CN group compared to the non-Hispanic MND groups. These findings show that decreased and increased TREM2 in membrane-bound fractions and in soluble-enriched fractions, respectively, is associated with increased Aβ and neuroinflammation in this cohort of HIV+ brains, particularly those identifying as Hispanics. These findings suggest a role for TREM2 in the brain of HIV+ individuals may deserve more investigation as a biomarker for HAND and as a possible therapeutic target. OPEN SCIENCE BADGES: This article has received a badge for *Open Materials* because it provided all relevant information to reproduce the study in the manuscript. The complete Open Science Disclosure form for this article can be found at the end of the article. More information about the Open Practices badges can be found at https://cos.io/our-services/open-science-badges/.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Neurochem

DOI

EISSN

1471-4159

Publication Date

December 2018

Volume

147

Issue

6

Start / End Page

784 / 802

Location

England

Related Subject Headings

  • Tumor Necrosis Factor-alpha
  • Retrospective Studies
  • Receptors, Immunologic
  • RNA, Messenger
  • Neuropsychological Tests
  • Neurology & Neurosurgery
  • Middle Aged
  • Microglia
  • Membrane Glycoproteins
  • Male
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Fields, J. A., Spencer, B., Swinton, M., Qvale, E. M., Marquine, M. J., Alexeeva, A., … Desplats, P. (2018). Alterations in brain TREM2 and Amyloid-β levels are associated with neurocognitive impairment in HIV-infected persons on antiretroviral therapy. J Neurochem, 147(6), 784–802. https://doi.org/10.1111/jnc.14582
Fields, Jerel Adam, Brian Spencer, Mary Swinton, Emma Martine Qvale, María J. Marquine, Arina Alexeeva, Sarah Gough, et al. “Alterations in brain TREM2 and Amyloid-β levels are associated with neurocognitive impairment in HIV-infected persons on antiretroviral therapy.J Neurochem 147, no. 6 (December 2018): 784–802. https://doi.org/10.1111/jnc.14582.
Fields JA, Spencer B, Swinton M, Qvale EM, Marquine MJ, Alexeeva A, et al. Alterations in brain TREM2 and Amyloid-β levels are associated with neurocognitive impairment in HIV-infected persons on antiretroviral therapy. J Neurochem. 2018 Dec;147(6):784–802.
Fields, Jerel Adam, et al. “Alterations in brain TREM2 and Amyloid-β levels are associated with neurocognitive impairment in HIV-infected persons on antiretroviral therapy.J Neurochem, vol. 147, no. 6, Dec. 2018, pp. 784–802. Pubmed, doi:10.1111/jnc.14582.
Fields JA, Spencer B, Swinton M, Qvale EM, Marquine MJ, Alexeeva A, Gough S, Soontornniyomkij B, Valera E, Masliah E, Achim CL, Desplats P. Alterations in brain TREM2 and Amyloid-β levels are associated with neurocognitive impairment in HIV-infected persons on antiretroviral therapy. J Neurochem. 2018 Dec;147(6):784–802.
Journal cover image

Published In

J Neurochem

DOI

EISSN

1471-4159

Publication Date

December 2018

Volume

147

Issue

6

Start / End Page

784 / 802

Location

England

Related Subject Headings

  • Tumor Necrosis Factor-alpha
  • Retrospective Studies
  • Receptors, Immunologic
  • RNA, Messenger
  • Neuropsychological Tests
  • Neurology & Neurosurgery
  • Middle Aged
  • Microglia
  • Membrane Glycoproteins
  • Male